Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3161 Target Snapshot

L-selectin · SINGLE PROTEIN · Homo sapiens

134Compounds
16Assays
0Approved Drugs
94.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

L-selectin shows late clinical disease relevance led by sickle cell anemia. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P14151. Start with sickle cell anemia, then reuse UniProt P14151 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with sickle cell anemia, then reuse UniProt P14151 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
sickle cell anemia

L-selectin shows late clinical disease relevance led by sickle cell anemia. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with sickle cell anemia because it currently carries late clinical support. Linked drugs include RIVIPANSEL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats L-selectin as ChEMBL target CHEMBL3161, mapped to UniProt P14151. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
L-selectin
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3161
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P14151
L-selectin
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether L-selectin is the right protein anchor across sources, using UniProt P14151 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why sickle cell anemia is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelL-selectin
UniProt AccessionP14151
Component TypeProtein
Sequence Length372 aa

L-selectin

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as L-selectin, mapped to UniProt P14151. Sequence length is 372 aa.

Mapped IDP14151
Review nameL-selectin
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

L-selectin shows late clinical disease relevance led by sickle cell anemia. 2 more disease programs remain visible in the same review block.

Late clinical Phase III
sickle cell anemia
1 linked drug · 1 direct · 1 efficacy
Linked drugRIVIPANSEL
Clinical signal Phase I
kidney disease
1 linked drug · 1 direct · 1 efficacy
Linked drugRIVIPANSEL
Clinical signal Phase I
liver disease
1 linked drug · 1 direct · 1 efficacy
Linked drugRIVIPANSEL
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with sickle cell anemia because it currently carries late clinical support. Linked drugs include RIVIPANSEL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasesickle cell anemia
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase II
Assay Mix

Activity Type Distribution

IC5094.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3351094 6.16 IC50 700.0 Preclinical
CHEMBL3351095 6.1 IC50 800.0 Preclinical
CHEMBL375763 6.1 IC50 790.0 Preclinical
CHEMBL112796 6.0 IC50 1000.0 Preclinical
CHEMBL220720 5.96 IC50 1100.0 Preclinical
CHEMBL221163 5.85 IC50 1400.0 Preclinical
CHEMBL220254 5.82 IC50 1500.0 Preclinical
CHEMBL223010 5.8 IC50 1600.0 Preclinical
CHEMBL3351093 5.8 IC50 1600.0 Preclinical
CHEMBL373592 5.8 IC50 1600.0 Preclinical
Distribution

pChEMBL Value Distribution

12
5.0
13
5.5
4
6.0
0
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

16
Total Assays
74
Tested Compounds
1
Assay Types
Binding — 16 assays, 74 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 10 56 5.2
cell-based format 5 16 4.5
assay format 1 2 4.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine